Search Within

Gregory J Riely

  1. "2024"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (9)
  3. Guidelines (2)
  4. Review (2)
  5. Editorial (1)
Groups
  1. Department of Medicine (25)
  2. Solid Tumor Oncology Division (25)
  3. Thoracic Oncology (25)
  4. GSK Faculty (11)
  5. Hematology-Oncology Fellows (11)
  6. Human Oncology and Pathogenesis Program (10)

More Groups

People
  1. Marc Ladanyi (8)
  2. Helena Yu (7)
  3. Michael Offin (5)
  4. Charles Rudin (4)
  5. Deborah Schrag (4)
  6. Mark Kris (4)

More People

Years
  1. 2024 (25)
Publications
  1. Journal of Clinical Oncology (6)
  2. Journal of the National Comprehensive Cancer Network (3)
  3. Annals of Oncology (2)
  4. JCO Precision Oncology (2)
  5. Journal of Thoracic Oncology (2)
  6. Acta Neuropathologica Communications (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (8)
  2. American Association for Cancer Research (4)
  3. Oxford University Press (4)
  4. Harborside Press (3)
  5. Elsevier Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
    Meeting Abstract

    Cobb, P. W.; Hochmair, M.; Schuler, M. H. H.; Riely, G. J.; Rojas, C. I.; Kim, S. J.; Chen, X.; Lara-Guerra, H.; Felip, E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Real-world experience with circulating tumor DNA in cerebrospinal fluid in patients with central nervous system tumors
    Meeting Abstract

    Hickman, R.; Miller, A. M.; Holle, B. M.; Jee, J.; Liu, S. Y.; Ross, D.; Yu, H.; Riely, G. J.; Ombres, C.; Gerwitz, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma and thymic carcinoma
    Meeting Abstract

    Marks, J. A.; Agarwal, S.; Ahn, J.; Reuss, J. E.; Altan, M.; Nabel, C.; Gutierrez, M. E.; Garassino, M. C.; Riely, G. J.; Wakelee, H.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Automated real-world data integration improves cancer outcome prediction
    Journal Article

    Jee, J.; Fong, C.; Pichotta, K.; Tran, T. N.; Luthra, A.; Waters, M.; Fu, C.; Altoe, M.; Liu, S. Y.; Maron, S. B.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
    Journal Article

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Iwama, E.; Inoue, T.; Rodríguez-Cid, J.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters
    Journal Article

    Zhao, B.; Dercle, L.; Yang, H.; Riely, G. J.; Kris, M. G.; Schwartz, L. H.
    Scientific Data (2024)

    Fulltext@MSK | Save
  • Characteristics and outcomes of patients with SMARCA4-deficient undifferentiated thoracic tumors
    Meeting Abstract

    Cooper, A.; Ricciuti, B.; Gagne, A.; Sholl, L.; Di Federico, A.; Awad, M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; Chaft, J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save